American Oncology Research and MiBA Form Strategic Alliance to Integrate Real-Time Data Intelligence with Community-Based Clinical Research
MWN-AI** Summary
On January 15, 2026, American Oncology Research (AOR) and Meaningful Insights Biotech Analytics (MiBA) announced a strategic alliance aimed at revolutionizing community oncology through the integration of real-time data intelligence. This collaboration seeks to address the persistent gap between static clinical trial protocols and the complex realities of patient care by combining AOR's robust site management capabilities with MiBA's advanced AI-enhanced data analytics.
The partnership focuses on transforming the clinical research landscape from a reactive framework into a proactive, data-driven process. By embedding intelligent data workflows within the American Oncology Network, the alliance aims to expedite the timeline from site selection to patient enrollment. This will allow AOR to leverage MiBA’s Real-World Data (RWD) capabilities for conducting feasibility analyses and patient matching, thus ensuring a more accurate and timely identification of eligible patient populations.
Katie Goodman, vice president of AOR, emphasized the need to modernize the infrastructure underlying patient care, highlighting how the alliance allows for the early identification of potential friction points throughout the research process. Similarly, Dr. Ralph V. Boccia, medical director of AOR, remarked that integrating real-time data into community research is essential for closing the gap between trial availability and patient need.
Moreover, the collaboration will enhance provider engagement by embedding research opportunities directly into clinical workflows via Electronic Medical Records (EMRs). This approach not only helps oncologists recognize clinical trials as immediate treatment options but also aligns with Diversity Action Plan (DAP) requirements, thereby fostering inclusivity in trial participation.
Overall, this strategic partnership signifies a significant step toward enhancing the efficiency and accessibility of clinical trials in community settings, ensuring that patients receive timely and innovative cancer care.
MWN-AI** Analysis
The strategic alliance between American Oncology Research (AOR) and Meaningful Insights Biotech Analytics (MiBA) marks a significant advancement in community-based oncology research, particularly through the integration of real-time data intelligence. This partnership is likely to enhance operational efficiency and patient access to clinical trials, addressing persistent challenges in the pharmaceutical industry.
Investors should consider the implications of this alliance on both companies' market positions. AOR’s established presence in community oncology, combined with MiBA's AI-driven data capabilities, creates a unique value proposition that could lead to expedited trial timelines and improved patient matching processes. This aligns well with the industry trend towards patient-centric research, as AOR can now leverage real-world data to optimize site selection and patient enrollment strategies significantly.
Furthermore, the integration of research opportunities in the clinical workflow potentially enhances oncologist engagement, allowing for trials to be viewed as immediate options. This evolution not only fosters greater trial participation but may also improve the quality of data collected through more diverse patient populations, satisfying regulatory compliance related to diversity in clinical trials.
From an investment perspective, the success of this alliance could improve revenue streams for both AOR and MiBA, given the increasing demand for innovative cancer treatments and the push towards value-based care. These factors position both entities for potential growth, particularly as community oncology becomes more mainstream.
However, potential investors should remain cautious. The integration of complex technologies and the need for seamless operational execution can present risks. Continuous monitoring of the partnership's outcomes, market response, and advancements in their operational models will be crucial for understanding the long-term financial health and growth prospects of AOR and MiBA in this dynamic market landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
FORT MYERS, Fla., Jan. 15, 2026 (GLOBE NEWSWIRE) -- American Oncology Research, LLC (AOR), and Meaningful Insights Biotech Analytics, LLC (MiBA), today announced a strategic partnership designed to align operational infrastructure with advanced data intelligence in community oncology. By integrating AOR’s site management capabilities with MiBA’s AI-enhanced data ecosystem, the alliance creates a unified framework that closes gaps between study design, site feasibility and patient access.
The collaboration addresses a longstanding challenge in the pharmaceutical industry: the disconnect between static clinical trial protocols and the dynamic reality of patient care. By embedding intelligent data workflows directly into the American Oncology Network (AON), the partnership aims to shift clinical research from a reactive administrative process to a proactive, data-informed discipline.
"To truly advance patient care, we must modernize the infrastructure that supports it," said Katie Goodman, vice president of research at American Oncology Research. "Our partnership with MiBA moves beyond traditional site management by operationalizing real-time data. This allows us to identify friction points before they occur—whether in feasibility, startup or enrollment—ensuring that the speed of research matches the urgency of our patients' needs."
Optimizing the Research Lifecycle
The alliance focuses on reducing the timeline between site selection and patient enrollment. By leveraging MiBA’s deep Real-World Data (RWD) capabilities, AOR can conduct feasibility analysis and patient matching based on contemporaneous network data. This provides a near-real-time view of eligible patient populations, enabling research teams to validate site viability and mobilize resources with greater precision.
“Integrating real-time data into community research is essential to closing the gap between trial availability and patient need,” said Ralph V. Boccia, MD, medical director of American Oncology Research. “This partnership strengthens our ability to identify eligible patients sooner, open trials more efficiently and ensure that life-changing therapies are accessible to individuals receiving care close to home.”
"The future of clinical development relies on the seamless convergence of care and research," said Mark Moch, managing partner at MiBA. "We are moving away from fragmented, siloed processes toward an integrated model where insights drive action. By embedding AI-powered intelligence into AOR’s clinical workflows, we are not just identifying patients; we are architecting a system where trials are accessible, efficient and aligned with the provider’s daily workflow."
Enhancing Provider Engagement and Trial Equity
A key component of the strategy is the integration of research opportunities directly into the point of care. The platform uses targeted insights within the Electronic Medical Record (EMR) environment to close the awareness gap for oncologists, ensuring clinical trials are presented as immediate and viable care options rather than retrospective considerations.
The partnership also strengthens the industry’s ability to meet Diversity Action Plan (DAP) requirements. With a holistic, data-driven operational model, AOR can proactively identify demographic barriers and implement inclusive enrollment strategies during study design. This approach reduces the risk of costly protocol amendments and supports more representative, high-quality data generation.
About American Oncology Research (AOR)
American Oncology Research (AOR) helps practices offer cutting-edge clinical trials without added burden. As part of the American Oncology Network (AON), we bring proven expertise, tailored site management services, and advanced tools to local practices—so more patients can access promising treatments right in their own communities.
We partner with research sites to streamline trial operations, from regulatory oversight to patient recruitment, financial tracking, and beyond. Our approach simplifies processes for providers and accelerates access for patients—without compromising quality, compliance, or care.
With AOR, practices can launch or expand trial offerings and deliver innovation locally-shaping the future of cancer care one patient at a time.
About Meaningful Insights Biotech Analytics
Meaningful Insights Biotech Analytics (MiBA) is a healthcare AI technology company on a mission to close the feedback loop between physicians, patients, and industry partners. The technology and data insights that MiBA generates supports pharmaceutical companies, research organizations, payers, biotech, health systems and providers to advance the quality of patient care. Learn more at www.mibaanalytics.com.
About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/769aca83-d193-4ea7-8d2c-0d7daf06ca6a
Contact:Karen Riley Sawyer-American Oncology NetworkKaren.Sawyer@AONcology.com
FAQ**
How will the partnership between American Oncology Research, LLC (AOR) and Meaningful Insights Biotech Analytics, LLC (MiBA) specifically enhance the operational infrastructure of the American Oncology Network Inc. AONC's clinical trial processes?
What metrics will American Oncology Network Inc. AONC use to measure the success of integrating real-time data into their clinical workflows, and how will this benefit patient care?
Can you elaborate on the ways in which American Oncology Network Inc. AONC plans to address demographic barriers in clinical trials through the newly developed data-driven operational model?
How does the collaboration between AOR and MiBA aim to shift the perception of clinical trials among oncologists within the American Oncology Network Inc. AONC and ensure they are viewed as viable treatment options?
**MWN-AI FAQ is based on asking OpenAI questions about American Oncology Network Inc. (OTC: AONC).
NASDAQ: AONC
AONC Trading
0.0% G/L:
$11.12 Last:
350 Volume:
$11.12 Open:
